| 摘要 |
The present invention relates to a pharmaceutical oral fixed dose combination comprising a) a therapeutically effective amount of Aliskiren, or a pharmaceutically acceptable salt thereof, b) a therapeutically effective amount of Valsartan, or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical oral fixed dose combination shows an in vitro dissolution of component (a) of 60% or less after 10 minutes and 95% or less after 20 minutes, and a dissolution profile of component (b) of 25% or more after 30 minutes, and 45% or more after 60 minutes at pH 4.5, said pharmaceutical oral fixed dose combination being bioequivalent to a free dose combination of Aliskiren and Valsartan.
|
